Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery
Randomized Clinical Trial of β Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery
Brigham and Women's Hospital
90 participants
Jun 10, 2026
INTERVENTIONAL
Conditions
Summary
The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
An orally-administered stable crystalline tablet formulation of NMN
matching placebo tablets
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07013591